Unicycive Therapeutics, Inc. is facing investigator findings regarding manufacturing compliance issues from the FDA.

The entities involved

• Unicycive Therapeutics, Inc. →

  Unicycive Theraputics (Nasdaq: UNCY) is a clinical-stage biotechnology company focused on developing kidney medications

  Nothing else this week.

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Nasdaq →

  American fully electronic stock exchange

  • Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
  • Vanguard Short-Term Inflation-Protected Securities ETF is disclosing its holdings to the SEC and trading on the Nasdaq electronic stock exchange.Mon 16:28

Related events

• Elutia is trading on the Nasdaq stock exchange and requires regulatory clearance from the FDA for product launches.Aug 15
• Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.Sep 2
• Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.Sep 22
• Cisco Systems, Inc. stock trades on the Nasdaq electronic exchange and is subject to required filings with the SEC.Aug 17
• Evergy stock trades on the Nasdaq electronic exchange and requires institutional investment disclosures with the SEC.Sep 3